A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GD1 / Gaucher disease type 1

[Related PubMed/MEDLINE]
Total Number of Papers: 43
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GD1  (>> Co-occurring Abbreviation)
Long Form:   Gaucher disease type 1
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Acoustic radiation force impulse point shear wave elastography of the liver and spleen in patients with Gaucher disease type 1: Correlations with clinical data and markers of disease severity. ARFI-pSWE
2020 Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. GlcSph, MG, Sap C
2020 Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1. Cmax, IM, PBPK
2020 Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study. ESI, MRM
2020 Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1. FD, HRQoL
2019 Drug-Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats. ---
2019 Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. GD
2019 Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. PH
2019 Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. ---
10  2019 Polyneuropathy in Gaucher disease type 1 and 3 - a descriptive case series. PNP, SFN
11  2019 Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1. AVN, BMB, DGS, VDR, WB-MRI
12  2018 Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States. ---
13  2018 Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients. GD, MRE
14  2018 Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. ---
15  2018 Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1. BMD, CALCR, ERT, VDR
16  2018 Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. PROMs
17  2018 Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial. AE
18  2017 A new framework for evaluating the health impacts of treatment for Gaucher disease type 1. SSC
19  2017 Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial. ---
20  2017 The modulation of inflammatory parameters, Brain-derived neurotrophic factor levels and global histone H4 acetylation status in peripheral blood of patients with Gaucher disease type 1. BDNF, CS, CT, GBA
21  2017 Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. ERT, ICGG, US
22  2016 Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. CL, ERT, LDL-C, TC
23  2016 Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naive to enzyme replacement therapy or previously treated with imiglucerase. ERT
24  2015 Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. ---
25  2015 Eliglustat: A Review in Gaucher Disease Type 1. EMs, ERT, PMs
26  2015 Seven-year safety and efficacy with velaglucerase alfa for treatment-naive adult patients with type 1 Gaucher disease. BMB, BMD
27  2014 Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. ---
28  2014 Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. AVN, GD
29  2014 Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. BMD
30  2013 Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. ERT, HDL, LDL, TG
31  2013 Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. ICGG
32  2013 Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. AEs, ERT
33  2011 Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia. ---
34  2011 Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. ---
35  2011 The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. GD, ICGG
36  2011 Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG). FROG
37  2010 A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. CI
38  2010 A validated disease severity scoring system for adults with type 1 Gaucher disease. ---
39  2009 A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. ---
40  2009 Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. ---
41  2008 Life expectancy in Gaucher disease type 1. ---
42  2007 Neurological and brain MRS findings in patients with Gaucher disease type 1. ---
43  2007 Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. ERT